28 February 2024
Authored and Edited by Dr. Moritz Meckel
The UPC Court of Appeal rendered its first substantive decision [1] on 26 February 2024. In re. 10x Genomics vs. NanoString, it revoked a preliminary injunction issued by the UPC local division in Munich.
Although the Court commented on many legal questions of the new UPC framework, the ultimate reason for the decision was the Court’s preliminary conclusion that the underlying patent probably lacks an inventive step.
It found that the prior art document D6 [2] discloses all features of the method of analysis subject to patent claim 1 except for the limitation that the method is applied to analytes "in a cell or tissue sample". This application, according to the Court of Appeal, was obvious to the skilled person in view of document D6 [2] alone or in combination with B30 [3].
The finding is just in preliminary proceedings and shall not be confused with a revocation of the patent as such.
[1] Original decision (in German): https://www.unified-patent-court.org/sites/default/files/upc_documents/576355-2023-AnordnungDE.final_.pdf
English translation: https://www.unified-patent-court.org/sites/default/files/upc_documents/576355-2023%20AnordnungEN.final_.pdf
[2] Document D6 = Jenny Göransson et al., „A single molecule array for digital targeted molecular analyses“, Nucleic Acids Research, 2009, Vol. 37, No. 1, e7 - https://academic.oup.com/nar/article/37/1/e7/1026581
[3] Document B30 = Magnus Stougaard et al., „In situ detection of non-polyadenylated RNA molecules using Turtle Probes and target primed rolling circle PRINS“, BMC Biotechnology 2007, 7:69, http://www.biomedcentral.com/1472-6750/7/69
Copyright © 2024 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Webinar
May 9, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
At the PTAB Blog
USPTO Releases Notice of Proposed Rule Making Codifying Several Precedential Case Factors
April 25, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.